Communiqués Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8077

Temps réel estimé Cboe BZX Autres places de cotation 17:34:06 28/06/2024			Varia. 5j.	Varia. 1 janv.
2,42 ^USD	+3,86%		-15,73%	-13,00%

29/05	Cellectar Biosciences, Inc. et City of Hope Cancer Center collaborent pour evaluer Iopofosine I 131 dans le mycosis fongoide	CI
14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape	16:07	AQ
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape	27/06	AQ
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides	29/05	AQ
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05	AQ
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05	AQ
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05	AQ
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03	AQ
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	18/03	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	AQ
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01	AQ
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25/01	AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23/01	AQ
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	22/01	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	17/01	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data	16/01	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	15/01	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	12/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8077

Communiqués

Filtres